The "Relapsed or Refractory Mycosis Fungoides (MF) and Sézary Syndrome (SS) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) market. A detailed picture of the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) pipeline landscape is provided, which includes the disease overview and Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) treatment guidelines.
The assessment part of the report embraces in-depth Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) commercial assessment and clinical assessment of the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) treatment.
- Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) market.
Scope of the Report
- The Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS).
Key Topics Covered
1. Report Introduction
2. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS)
2.1. Overview
2.2. History
2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Diagnosis
2.6.1. Diagnostic Guidelines
3. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Current Treatment Patterns
3.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Treatment Guidelines
4. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Late Stage Products (Phase-III)
7. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Discontinued Products
13. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Key Companies
15. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Unmet Needs
18. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Future Perspectives
19. Relapsed or Refractory Mycosis Fungoides (MF) AND Szary Syndrome (SS) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Companies Mentioned
- Sorrento Therapeutics, Inc.
- Hoffmann-La Roche
- Mallinckrodt
- Innate Pharma
- 4SC AG
- Seattle Genetics, Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nfdd1l
View source version on businesswire.com: https://www.businesswire.com/news/home/20200702005389/en/
Contacts:
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
